The ACTIONED Consortium: integrAted moleCular soluTIons fOr diagNostics and Early Detection

Active(用于诊断和早期检测的集成分子解决方案)由三个主要合作伙伴组成的财团：1.基因组学/基于组织的癌症诊断方面的国家领先专家(贝尔法斯特女王大学或PMC的精准医学卓越中心)2.癌症基因组和组织诊断方面的全球领先诊断解决方案提供商(罗氏)3.在人工智能工具和相关分析框架(Sonrai Analytics)方面取得初步成功的英国中小企业这些合作伙伴以前已经合作过，提供在NHS的诊断实验室中常规使用的产品。这种雄心勃勃的合作伙伴关系的目的是在PMC最先进的认证实验室中建立所有与基因组学和基于组织的癌症诊断相关的技术和软件：a)基因组学，通过一种名为下一代测序的技术，是目前癌症患者个性化药物治疗的主要驱动力。b)数字病理学和人工智能正在改变我们从事传统病理学的方式，提供迄今未知的一定程度的客观性和质量控制。一旦建立，三方将致力于这两个途径之间的必要集成，影响测试质量/负担能力和临床决策。ACTIONED将提供以结直肠癌为样本的集成，一个适用于所有其他癌症类型的模型，解决两个关键需求未得到满足的场景。首先，准确检测II期和III期结直肠癌患者的早期复发，从那些可以避免治疗毒性的人中识别那些真正从治疗中受益的人。第二，发现真正的早期结直肠癌，作为一项原则证明。采取行动将推动我们的经济增长。事实上，Actioned将集中在北爱尔兰，提供分析/临床产品，供NHS作为一个整体采用。这将加强我们作为全球医疗保健知识和专有技术整合开发领导者的地位。具体地说：a)Sonrai Analytics将发展成为一个非常有益的市场地位b)PMC将成为全球癌症研究的强大参考实验室。c)罗氏将为其产品提供更好的价值。最后，ACTIONED将通过目前在贝尔法斯特女王大学非常成功的MSC提供世界领先的教育。从战略上讲，ACTIONED内的PMC-罗氏-Sonrai合作伙伴关系是前所未有的联盟；1.罗氏的技术和样本承诺2.Sonrai能够改善罗氏平台3之间的连接和集成，PMC完全集成和认可的实验室框架以及强大的分子诊断专业知识已付诸行动，Sonrai将展示这种集成在我们的NHS中的影响，并改善我们癌症患者的生活。

ACTIONED (integrAted moleCular soluTIons fOr diagNostics and Early Detection) in a consortium of three main partners:1.National leading experts in genomics/tissue-based cancer diagnostics (The Precision Medicine Centre of Excellence at Queen's University Belfast or PMC)2.The leading global provider of diagnostic solutions in cancer genomics and tissue diagnostics (Roche)3.A UK SME with early success in artificial intelligence tools and related analytical frameworks (Sonrai Analytics)These partners have already worked together before, delivering products that routinely used in diagnostic laboratories in the NHS.The purpose of this ambitious partnership is to establish, in PMC's state-of-the-art accredited laboratory, all technology and software relating to genomics and tissue-based cancer diagnostics:a)Genomics, through a technology called Next Generation Sequencing, is the current main driver of personalised medicine to cancer patients.b)Digital Pathology and Artificial Intelligence is transforming the way we practice traditional pathology, delivering a degree of objectivity and quality-control unknown to date.Once established, the 3 parties will work on the integration necessary between these two pathways, impacting testing quality/affordability and clinical decision-making.ACTIONED will provide integration using colorectal cancer as an exemplar, a model to be applicable to all other cancer types, addressing two scenarios of critical unmet need. Firstly, accurate detection of early recurrence in stage II and III colorectal cancer patients, identifying those who will truly benefit from therapy from those who can be spared therapeutic toxicity. Secondly, detection of true early colorectal cancer, addressed as a proof-of-principle.ACTIONED will drive growth in our economy. Indeed, ACTIONED will be centered in Northern Ireland, providing an analytical/clinical product to be adopted by the NHS as a whole. This will enhance our position as leaders in development of healthcare knowledge and know-how integration at a global scale. Specifically:a) Sonrai Analytics will develop into a market position of great benefitb) PMC will become a strong reference laboratory for cancer studies globally.c) Roche will have a better value for its product.Finally, ACTIONED will deliver world-leading education through a very successful MSc currently run in Queen's University Belfast.Strategically, the PMC-Roche-Sonrai partnership within ACTIONED is an unprecedented coalition;1. Roche's technological and sample commitment2. Sonrai's capability to improve connectivity and integration between Roche platforms3, PMC's fully integrated and accredited laboratory framework and strong molecular diagnostic know-howTogether, ACTIONED will show the impact of this integration in our NHS, and improve the lives of our cancer patients.